April 12, 2025 – Meishu Biotech, a trailblazer in innovative healthcare solutions, proudly announces the launch of Osteahenz, a revolutionary brand in the orthopedic segment. Backed by a patent-pending formula, Osteahenz introduces the Synoregen Complex, featuring the cutting-edge MRELF MultiCollagen Peptide combined with the...
Meishu Biotech, a leader in biotechnology and pharmaceuticals, has unveiled OSTEAHENZ, a breakthrough treatment for osteoporosis. This patent-applied product is India’s first in the orthopedic segment and promises a transformative approach to addressing a condition that affects millions of people, particularly the elderly.
Osteoporosis, a...
Meishu Biotech in Collaboration with MEISHU Sg. is making significant strides in the orthopedic sector by introducing,
India's first patent-applied brand that targets both osteoblasts and osteoclasts.
This innovative approach is set to revolutionize treatment options for bone-related disorders, particularly in the context of osteoporosis and...
Meishu Biotech is concentrating on a special Patent applied transport mechanism that improves medicine delivery to damaged joints in order to further the treatment of osteoarthritis (OA) with its patent applied SYNOREGEN complex. Which is India's first.
This complex makes use of a special combination...
